Cargando…

Narciclasine, a novel topoisomerase I inhibitor, exhibited potent anti-cancer activity against cancer cells

DNA topoisomerases are essential nuclear enzymes in correcting topological DNA errors and maintaining DNA integrity. Topoisomerase inhibitors are a significant class of cancer chemotherapeutics with a definite curative effect. Natural products are a rich source of lead compounds for drug discovery,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Meichen, Liang, Leilei, Wang, Rong, Jia, Shutao, Xu, Chang, Wang, Yuting, Luo, Min, Lin, Qiqi, Yang, Min, Zhou, Hongyu, Liu, Dandan, Qing, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462586/ https://www.ncbi.nlm.nih.gov/pubmed/37640882 http://dx.doi.org/10.1007/s13659-023-00392-1

Ejemplares similares

Conversion of Natural Narciclasine to Its C-1 and C-6 Derivatives and Their Antitumor Activity Evaluation: Some Unusual Chemistry of Narciclasine †
por: Goulart Stollmaier, Juana, et al.
Publicado: (2022)

Narciclasine attenuates sepsis-induced myocardial injury by modulating autophagy
por: Tang, Rong, et al.
Publicado: (2021)

Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells
por: Lv, Chao, et al.
Publicado: (2022)

Concentration-dependent effects of narciclasine on cell cycle progression in Arabidopsis root tips
por: Na, Xiaofan, et al.
Publicado: (2011)

Narciclasine attenuates diet-induced obesity by promoting oxidative metabolism in skeletal muscle
por: Julien, Sofi G., et al.
Publicado: (2017)

Novel bivalent securinine mimetics as topoisomerase I inhibitors
por: Hou, Wen, et al.
Publicado: (2017)

Narciclasine, an isocarbostyril alkaloid, has preferential activity against primary effusion lymphoma
por: Gopalakrishnan, Ramakrishnan, et al.
Publicado: (2020)

Design and Synthesis of C-1 Methoxycarbonyl Derivative of Narciclasine and Its Biological Activity
por: Habaz, Lihi, et al.
Publicado: (2022)

Narciclasine induces autophagy-mediated apoptosis in gastric cancer cells through the Akt/mTOR signaling pathway
por: Yuan, Yunfeng, et al.
Publicado: (2021)

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
por: McKenzie, Jodi A, et al.
Publicado: (2017)

Lapcin, a potent dual topoisomerase I/II inhibitor discovered by soil metagenome guided total chemical synthesis
por: Wang, Zongqiang, et al.
Publicado: (2022)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Small DNA circles as bacterial topoisomerase I inhibitors
por: Li, Dawei, et al.
Publicado: (2019)

Narciclasine inhibits phospholipase A2 and regulates phospholipid metabolism to ameliorate psoriasis-like dermatitis
por: Kong, Yi, et al.
Publicado: (2023)

Narciclasine improves outcome in sepsis among neonatal rats via inhibition of calprotectin and alleviating inflammatory responses
por: Kingsley, Manoj Kumar, et al.
Publicado: (2020)

Evodiamine Stabilizes Topoisomerase I-DNA Cleavable Complex to Inhibit Topoisomerase I Activity
por: Chan, Agnes L.-F., et al.
Publicado: (2009)

The Deubiquitinating Enzyme Inhibitor PR-619 is a Potent DNA Topoisomerase II Poison
por: Cowell, Ian G., et al.
Publicado: (2019)

Narciclasine attenuates LPS-induced acute lung injury in neonatal rats through suppressing inflammation and oxidative stress
por: Duan, Qingning, et al.
Publicado: (2020)

Effect of safranal on the response of cancer cells to topoisomerase I inhibitors: Does sequence matter?
por: Lozon, Lama, et al.
Publicado: (2022)

Topoisomerase I in Human Disease Pathogenesis and Treatments
por: Li, Min, et al.
Publicado: (2016)

The Aza-Analogous Benzo[c]phenanthridine P8-D6 Acts as a Dual Topoisomerase I and II Poison, thus Exhibiting Potent Genotoxic Properties
por: Aichinger, Georg, et al.
Publicado: (2020)

Topoisomerase Inhibitors Have Potent Differentiation‐inducing Activity for Human and Mouse Myeloid Leukemia Cells
por: Nakaya, Kazuyasu, et al.
Publicado: (1991)

Haemanthus coccineus extract and its main bioactive component narciclasine display profound anti-inflammatory activities in vitro and in vivo
por: Fuchs, Simone, et al.
Publicado: (2015)

Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents
por: Yakkala, Prasanna Anjaneyulu, et al.
Publicado: (2023)

Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules
por: Matsuno, Yusuke, et al.
Publicado: (2018)

Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor
por: Shin, Weon Sup, et al.
Publicado: (2016)

QSAR Modeling on Benzo[c]phenanthridine Analogues as Topoisomerase I Inhibitors and Anti-cancer Agents
por: Thai, Khac-Minh, et al.
Publicado: (2012)

Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors
por: Madkour, Moustafa M., et al.
Publicado: (2023)

Gibberellin derivative GA-13315 overcomes multidrug resistance in breast cancer by up-regulating BMP6 expression
por: Luo, Xianqiang, et al.
Publicado: (2022)

Potent Anti-Ovarian Cancer with Inhibitor Activities on Both Topoisomerase II and (V600E)BRAF of Synthesized Substituted Estrone Candidates
por: El-Naggar, Mohamed, et al.
Publicado: (2019)

Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β
por: Ortega, Jose Antonio, et al.
Publicado: (2020)

Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo
por: Chen, Chun-Han, et al.
Publicado: (2016)

Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines
por: Minagawa, Yukihisa, et al.
Publicado: (1997)

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets
por: Gilbert, D C, et al.
Publicado: (2012)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2023)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
por: Gerrits, C. J., et al.
Publicado: (1997)

Encapsulation and Enhanced Delivery of Topoisomerase I Inhibitors in Functionalized Carbon Nanotubes
por: Chae, Sieun, et al.
Publicado: (2018)

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
por: Cincinelli, Raffaella, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vvf746s30un6rk8j2h4hi91uj6